Communication Experiences of Neurological Voice Disorder Patients With Automatic Voice Assistants and Human Listeners.
Abstract
[OBJECTIVES] Automated voice assistants (AVAs) are increasingly important to modern communication. Neurological voice disorders (NVDs) impair voice quality and speech intelligibility, leading to communication challenges. Although dysphonia disrupts communication with human listeners, the communication experience with AVA is unknown for individuals with NVDs. This study aimed to investigate self-reported communication experiences across AVA and human interactions for individuals with NVDs.
[STUDY DESIGN] Cross-sectional METHODS: The patient group comprised individuals with NVDs who were planning to receive botulinum toxin for their voice. The control group consisted of vocally typical adults. All participants provided HIPAA (Health Insurance Portability and Accountability Act) release and completed a novel five-item speech communication experience survey (SCES) and the speech handicap index (SHI). Fisher's exact test and two-sided t tests were used to compare results between groups.
[RESULTS] Across SCES items, the NVD group (n = 46) reported greater self-perceived communication challenges compared with the control group (n = 90) with familiar listeners (false discovery rate [FDR] = 0.0008), unfamiliar listeners (FDR = 0.0008), and AVAs (FDR = 0.0008). The NVD group interacted more with AVA (0.04) and liked AVA less (0.0037). Additionally, the NVD group reported significantly higher SHI total scores than the control group (P < 0.0001).
[CONCLUSIONS] Individuals with NVDs, undergoing botulinum toxin treatment, experience substantial speech-related communication barriers with humans and AVAs. Study findings expand knowledge of NVD communication experience and highlight the need for inclusive speech technology.
[STUDY DESIGN] Cross-sectional METHODS: The patient group comprised individuals with NVDs who were planning to receive botulinum toxin for their voice. The control group consisted of vocally typical adults. All participants provided HIPAA (Health Insurance Portability and Accountability Act) release and completed a novel five-item speech communication experience survey (SCES) and the speech handicap index (SHI). Fisher's exact test and two-sided t tests were used to compare results between groups.
[RESULTS] Across SCES items, the NVD group (n = 46) reported greater self-perceived communication challenges compared with the control group (n = 90) with familiar listeners (false discovery rate [FDR] = 0.0008), unfamiliar listeners (FDR = 0.0008), and AVAs (FDR = 0.0008). The NVD group interacted more with AVA (0.04) and liked AVA less (0.0037). Additionally, the NVD group reported significantly higher SHI total scores than the control group (P < 0.0001).
[CONCLUSIONS] Individuals with NVDs, undergoing botulinum toxin treatment, experience substantial speech-related communication barriers with humans and AVAs. Study findings expand knowledge of NVD communication experience and highlight the need for inclusive speech technology.
추출된 의학 개체 (NER)
| 유형 | 영어 표현 | 한국어 / 풀이 | UMLS CUI | 출처 | 등장 |
|---|---|---|---|---|---|
| 시술 | botulinum toxin
|
보툴리눔독소 주사 | dict | 2 | |
| 합병증 | AVAs
→ Automated voice assistants
|
scispacy | 1 | ||
| 약물 | [OBJECTIVES]
|
scispacy | 1 | ||
| 약물 | [CONCLUSIONS]
|
scispacy | 1 | ||
| 질환 | Neurological Voice Disorder
|
C0027765
nervous system disorder
|
scispacy | 1 | |
| 질환 | Neurological voice disorders
|
C0027765
nervous system disorder
|
scispacy | 1 | |
| 질환 | dysphonia
|
C1527344
Dysphonia
|
scispacy | 1 | |
| 질환 | SCES
→ speech communication experience survey
|
scispacy | 1 | ||
| 질환 | NVD
|
scispacy | 1 | ||
| 기타 | Patients
|
scispacy | 1 | ||
| 기타 | Human
|
scispacy | 1 | ||
| 기타 | patient
|
scispacy | 1 | ||
| 기타 | participants
|
scispacy | 1 | ||
| 기타 | AVAs
→ Automated voice assistants
|
scispacy | 1 | ||
| 기타 | SHI
→ speech handicap index
|
scispacy | 1 | ||
| 기타 | humans
|
scispacy | 1 |
🔗 함께 등장하는 도메인
이 논문이 속한 카테고리와 같은 논문에서 자주 함께 다뤄지는 카테고리들
관련 논문
- Local therapeutic strategies for neurocutaneous dysesthesia: from capsaicin to cannabinoids.
- Comparative efficacy of intralesional therapies for keloid scars: a network meta-analysis.
- Adverse neurological events following botulinum toxin type A: A case series of post-injection seizures and paralysis.
- Decreased utilization of component separation techniques over time in complex abdominal wall reconstruction following introduction of preoperative botulinum toxin A.
- Current Perspectives on Pectoralis Minor Syndrome: A Narrative Review.